KalVista Pharmaceuticals (KALV) Equity Average (2015 - 2025)

KalVista Pharmaceuticals' Equity Average history runs 11 years deep, the most recent figure standing at $68.1 million for Q3 2025.

• In Q3 2025, Equity Average fell 64.1% year-over-year to $68.1 million; the TTM figure through Jul 2025 stood at $68.1 million (down 64.1% YoY), while the FY2025 annual figure was $151.0 million, down 17.85% from the prior year.
• Equity Average came in at $68.1 million for Q3 2025 at KalVista Pharmaceuticals, down from $129.9 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $250.8 million in Q3 2021 to a low of $61.8 million in Q1 2021.
• A 5-year average of $158.0 million and a median of $154.2 million in 2022 frame the typical range for Equity Average.
• Across the five-year window, Equity Average surged 252.43% in 2022 and sank 64.1% in 2025, its largest moves.
• KalVista Pharmaceuticals' Equity Average stood at $236.0 million in 2021, then plunged by 34.65% to $154.2 million in 2022, then fell by 17.71% to $126.9 million in 2023, then rose by 17.56% to $149.2 million in 2024, then slumped by 54.36% to $68.1 million in 2025.
• According to Business Quant data, Equity Average over the past three periods registered $68.1 million, $129.9 million, and $149.2 million for Q3 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison